Financial Analysis: ObsEva (OBSV) versus The Competition
ObsEva (NASDAQ: OBSV) is one of 290 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare ObsEva to similar businesses based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, valuation, dividends and risk.
Valuation & Earnings
This table compares ObsEva and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|ObsEva Competitors||$290.27 million||$35.99 million||58.88|
Insider & Institutional Ownership
35.9% of ObsEva shares are held by institutional investors. Comparatively, 49.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares ObsEva and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings for ObsEva and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ObsEva presently has a consensus price target of $20.33, indicating a potential upside of 108.98%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.44%. Given ObsEva’s stronger consensus rating and higher possible upside, equities research analysts clearly believe ObsEva is more favorable than its rivals.
ObsEva rivals beat ObsEva on 7 of the 12 factors compared.
ObsEva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea. OBE001 (nolasiban) is an oral, new generation oxytocin antagonist with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART). BE022 is an orally active small molecule dinoprost (PGF2a) receptor antagonist.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.